Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | POLD1 | P28340 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492073 | 1.00 | POLG (0.68) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL8409011 | 0.89 | POLG (0.70) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL8409014 | 0.89 | POLG (0.70) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25492503 | 0.89 | POLG (0.70) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25492066 | 0.88 | POLG (0.62) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492013 | 0.88 | POLG (0.62) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492567 | 0.88 | POLG (0.62) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492103 | 0.85 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL25492015 | 0.85 | POLG (0.50) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL24351647 | 0.84 | POLB (0.50) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151046-A1 | 5-POSITION MODIFIED PYRIMIDINES | NUCLERA LTD (GB) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151046-A1 | 5-POSITION MODIFIED PYRIMIDINES | RNGTT, NSUN2, DPYD | POLG 157/4885ALB 4774/4885P2RY2 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.